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Abstract
Background: The potentially serious nature of herpes zoster (HZ) and the long-term complication post-herpetic 
neuralgia (PHN) are often underestimated. One in four people will contract herpes zoster in their lifetime, with this risk 
rising markedly after the age of 50 years, and affecting one in two in elderly individuals. Pain is the predominant 
symptom in all phases of HZ disease, being reported by up to 90% of patients. In the acute phase, pain is usually 
moderate or severe, with patients ranking HZ pain as more intense than post-surgical or labour pains. Up to 20% of 
patients with HZ develop PHN, which is moderate-to-severe chronic pain persisting for months or years after the acute 
phase. We review the available data on the effect of HZ and PHN on patients' quality-of-life.
Discussion: Findings show that HZ, and particularly PHN, have a major impact on patients' lives across all four health 
domains - physical, psychological, functional and social. There is a clear correlation between increasing severity of pain 
and greater interference with daily activities. Non-pain complications such as HZ ophthalmicus can increase the risk of 
permanent physical impairment. Some elderly individuals may experience a permanent loss of independence after an 
acute episode of HZ. Current challenges in the management of HZ and PHN are highlighted, including the difficulty in 
administering antiviral agents before pain becomes established and the limited efficacy of pain treatments in many 
patients. We discuss the clinical rationale for the HZ vaccine and evidence demonstrating that the vaccine reduces the 
burden of the disease. The Shingles Prevention Study, conducted among >38,000 people aged ≥60 years old, showed 
that the HZ vaccine significantly reduces the burden of illness and the incidence of both HZ and PHN. In the entire 
study population, zoster vaccination reduced the severity of interference of HZ and PHN with activities of daily living by 
two-thirds, as measured by two questionnaires specific to HZ.
Summary: A vaccination scheme may positively impact the incidence and course of HZ disease, thereby improving 
patients' quality-of-life.
Background
Herpes zoster (HZ) is a common, painful and debilitating
condition caused by a reactivation of the varicella-zoster
virus (VZV) from a latent infection of sensory ganglia [1-
3]. The disease course can be divided into four phases:
prodrome, acute, subacute and chronic [4]. The pro-
drome occurs 1-5 days before the onset of HZ rash in
70%-80% of cases [5]. Symptoms are non-specific and
range from itching to an intense burning sensation [6].
General constitutional symptoms (for example, fever,
malaise, headaches) may also occur [5]. The acute phase
of HZ disease is characterised by a vesicular skin rash in
the affected dermatome which is usually accompanied by
acute pain [5,7]. Acute HZ is usually defined as occurring
up to 30 days after rash onset [8]. In patients who subse-
quently develop chronic disease, there is a subacute phase
(30-90 days after rash onset) [9].
Post-herpetic neuralgia (PHN) is the most common
complication of HZ. A standard definition for PHN is
lacking, but it is often defined as pain that persists for ≥90
days after the onset of HZ rash [8]. The chronic pain of
PHN is debilitating and can persist for months or years
after the acute disease phase [10,11]. Studies vary in the
reporting of the duration of persistent pain [12]. In one
study of patients aged ≥65 years, the mean duration of
pain was 3.3 years, and ranged from 3 months to more
than 10 years [13].
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The lifetime risk of contracting HZ is one in four, but
this risk increases markedly after 50 years of age due to an
age-related decline in VZV-specific cell-mediated immu-
nity [6,14,15]. PHN incidence also increases rapidly in
individuals after the age of 60 years [16,17]. Of patients
with HZ who are ≥50 years old, as many as 10%-20% will
develop PHN [11].
HZ is incorrectly perceived by many clinicians to be a
mild and readily treatable disease. In fact, treatment
options remain inadequate -- particularly for PHN -- and
the disease can have devastating effects on patients' qual-
ity-of-life (QoL) in the acute and chronic phases
[13,18,19]. These effects are widespread, affecting
patients' physical and psychological health, as well as
their ability to continue normal daily and social activities.
Non-pain complications (for example, ophthalmic, neu-
rological) are also a problem in patients with HZ [20].
This contribution discusses the available data on the
impact of HZ and PHN on the QoL and functional status
of patients and highlights the current challenges in their
management. An increased awareness of the substantial
burden of HZ and PHN on QoL is essential and may lead
to an improvement in prevention and management strat-
egies.
Discussion
The World Health Organization defines health as 'a state
of complete physical, mental and social wellbeing, and
not merely the absence of disease or infirmity' [21]. The
term QoL, describes the overall sense of wellbeing that a
person is experiencing, and how well that person can live
a  l i f e  t h a t  i s  n o r m a l  f o r  t h e m  [ 2 2 ] .  E l e m e n t s  o f  Q o L
include basic activities (for example, managing to bathe,
dress and eat), complex activities (for example, shopping
and carrying out household chores), emotional wellbeing
(for example, level of fear, anxiety, distress and ability to
concentrate) and enjoying relationships with family,
friends and social groups.
Clinical studies should assess all aspects of the life and
health of a patient in order to establish how a disease or
treatment affects their QoL [23]. Health-related QoL
instruments measure four key health domains -- physical,
psychological, social and functional (the latter includes
the basic activities of daily living; ADL [18,23,24].
In patients with HZ and PHN, the QoL analyses rely on
subjective self-reporting using generic, standardized and
validated health-status questionnaires such as EuroQoL
and Short form (SF)-12 [19]. These generic tools are used
to measure the impact of a disease on QoL consistently
across the four domains of health in all types of patients
and general populations [25]. The McGill Pain Question-
naire Present Pain Intensity (a generic tool for pain
assessment) is also frequently used because pain is part of
health status in the context of diseases such as HZ and
PHN [19].
Two questionnaires have been specifically developed to
assess how the pain and discomfort associated with HZ
and PHN diminish functional capacity: the Zoster Brief
Pain Inventory (ZBPI) [19,26] and the Zoster Impact
Questionnaire (ZIQ) [19]. The ZBPI measures the impact
of the pain and discomfort caused by HZ or PHN on the
ability to carry out seven general activities: work, sleep,
walking, life enjoyment, mood, relations with others and
general activity [19,26]. This tool, therefore, determines
the effect of HZ and PHN on QoL across all four domains
of health. The ZIQ assesses how HZ pain and PHN affect
the functional aspects of life (bathing, grooming, dress-
ing, concentration, preparing meals, eating meals, house-
work, leisure activities, leaving the house, shopping,
travelling). The ZIQ is more focused on daily activities
than the ZBPI [19]. The ZBPI has been evaluated against
other validated pain questionnaires, but the ZIQ has not
[19]. Both of these tools are recognized as sensitive and
r e l i a b l e  m e a s u r e s  o f  t h e  i m p a c t  o f  H Z  a n d  P H N  o n
patients' daily lives [19,27].
Impact of HZ-related pain on QoL and ADL
Pain is usually the predominant symptom in all phases of
HZ disease, being reported by up to 90% of patients [28].
The intensity of pain in patients with HZ and PHN is
assessed using subjective self-reporting. Patients are
asked to rate their level of HZ/PHN pain (for on average
or at its worst) on a numerical rating scale from 0 (no
pain) to 10 (pain as bad as you can imagine).
Features of HZ pain
M o s t  p a t i e n t s  w i t h  a c u t e  H Z  e x p e r i e n c e  m o d e r a t e  o r
severe dermatomal pain in the skin innervated by the
afflicted ganglion [11]. Acute-phase pain is due to the
damage to neuronal tissues as a result of viral replication
and immune responses [1,29]. Patients rank pain during
the acute phase as more intense than post-surgical or
labour pain [30].
Pain in the acute phase can be constant or intermittent
and may show varied symptoms, such as burning or stab-
bing sensations, itching, tingling or numbness, angina-
like aching or squeezing sensations and a deep aching or
'pulled muscle' sensation [10]. Many patients present with
tactile allodynia (pain from a stimulus that is not nor-
m a lly  pa inful )  su c h as t he  t o uc h of  c lot hing  o r a  l igh t
breeze across the skin [10]. Allodynia can be very dis-
abling and may predict a higher risk of developing PHN
[9]. Other PHN predictive factors include the presence of
prodromal pain, severity of rash, severity of pain and
ophthalmic localization [31-35].
Impact of HZ pain on Qol
The substantial impact of acute-phase pain on QoL is
being increasingly recognized, with QoL studies showingJohnson et al. BMC Medicine 2010, 8:37
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effects on patients' lives across all four health domains
(Table 1) [18,19,24,26,36-38]. Many patients report that
pain during the acute phase of HZ impacts 'quite a bit' or
'extremely' on their physical, role and social functioning
[18]. Depression is also reported by patients with acute
symptoms of HZ [18]. In a study of 50 patients with
acute-phase HZ aged 54-94 years, a clear correlation
between increased pain intensity and greater interference
with activities (including general activity, work, sleep and
enjoyment of life) was observed (Figure 1) [36]. At a mod-
erate pain level of 4, 20%-30% reported interference but,
at a high pain level of 9 or 10, ≥ 66% reported an effect on
each activity.
Different components of acute-phase pain impact on
different health domains. This has been demonstrated by
multivariate analyses, controlling for patients' demo-
graphic and clinical variables [18]. Data showed that sig-
nificant independent contributions were made by sensory
components of pain to poor physical functioning, affec-
tive components of pain to depression and psychological
impairment and overall pain burden (sensory and affec-
tive combined) to poor social and role functioning.
Some elderly individuals may experience a permanent
loss of independence, never fully regaining their lifestyles,
interests and levels of activity after an acute episode of
HZ [24].
Clinical features of PHN
PHN is characterized by constant and/or intermittent
paroxysmal pain persisting for ≥90 days after the onset of
HZ rash [8,10]. For some patients, PHN is a continuation
of the painful symptoms of the acute phase of HZ; others
experience completely different pains and sensations.
Allodynia is present in ≥70% of patients and is usually
considered to be the most distressing and debilitating
PHN component [10,28]. Numbness and tingling also
contribute to the PHN burden [10]. Clinically, there is an
area of scarred skin, which denotes sensory loss and the
wider area of dynamic mechanical allodynia. Other neu-
ropathic features include burning, electric shocks, pins
and needles and itching. The 'neuropathic itch' in PHN
patients may lead to injury in those who scratch itchy skin
so much that loses its protective sensation [39].
Most patients categorise the intensity of PHN as mod-
erate-to-severe (pain scores ≥4 on a scale of 0-10) despite
receiving analgesic agents [40]. The persistency of PHN
means that patients have few periods of respite from
erratic, painful and prolonged attacks.
Impact of PHN on Qol
Reduced QoL is a particular problem in patients whose
pain persists as PHN. The impact of PHN on patients'
lives is substantial and apparent across all domains of
QoL (Table 1, Figure 2) [13,19,37,38,40-42]. There is a
positive correlation between increasing pain severity and
the extent of the negative impact on QoL [13]. In a study
that assessed the impact of pain, medication use and QoL
in 385 patients with PHN aged >65 years, 40% of respon-
dents said that pain moderately to severely affected their
ability to carry out general activities (Figure 2) [13]. In
addition, 48% of patients commented that pain interfered
moderately or severely with their enjoyment of life (Fig-
ure 2) [13].
PHN causes a loss of physical function, with patients
experiencing fatigue, anorexia, weight loss, reduced
mobility, physical inactivity, sleep disturbance (especially
insomnia) and reductions in overall health [8,13]. PHN
makes undertaking basic tasks (for example, bathing,
dressing, eating) and complex activities (for example,
travelling, performing household chores, shopping) diffi-
cult [8]. Institutionalization and a loss of autonomy can
occur in elderly patients with PHN [24]. The loss of social
contact, withdrawal and isolation can occur in patients
with PHN because they experience reduced indepen-
dence and participate less in social gatherings [8,24].
PHN may also affect patients' psychological wellbeing
[13,34]. Psychosocial scores improve in patients who fully
recover from the acute symptoms of HZ, but they remain
low in patients who develop PHN [34]. Patients with
intense pain are at greater risk of anxiety and depression
than those who report milder pain [8,13]. Patients with
PHN report difficulty in concentrating [24]. They also
fear recurrences of PHN symptoms and may experience
changes in their emotional roles within key relationships.
A substantial proportion of patients receive medication
for depression, anxiety and sleep disturbances related to
Table 1: Impact of herpes zoster and post-herpetic 
neuralgia on all four health domains 
Physical Psychological
Fatigue Depression
Anorexia Anxiety
Weight loss Emotional distress
Reduced mobility Difficulty concentrating
Physical inactivity Fear
Insomnia
Social Functional
Withdrawal Dressing, bathing, eating, 
mobility
Isolation Travelling, cooking, 
housework, shopping
Attendance at fewer social 
gatherings
Loss of independence
Change in social roleJohnson et al. BMC Medicine 2010, 8:37
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PHN [40]. Some patients became suicidal as a direct con-
sequence of PHN [38].
Non-pain symptoms and complications of HZ may also 
affect QoL
Several typical symptoms of HZ can be debilitating for
patients, even among those who do not experience clini-
cally meaningful pain [43]. The main characteristic of the
acute phase of HZ is the rash which, together with subse-
quent scarring, may be unsightly [28].
HZ can also give rise to non-pain complications, many
of which can increase the risk of permanent or long-
standing physical impairment [20]. Complications can be
ophthalmic (for example, herpes zoster ophthalmicus),
neurological (for example, cranial and peripheral nerve
palsies), dermatological (for example, bacterial super-
infection) or visceral (for example, pneumonia; Table 2)
[20]. A degree of motor deficit is common in patients
with HZ; severe and long-lasting paresis may rarely occur
if HZ affects the cervical and lumbosacral dermatomes
[44]. HZ patients may also be at greater risk of stroke.
Two recent retrospective population-based studies in
Taiwan found that HZ and herpes zoster ophthalmicus
patients had a 1.31-fold and 4.52-fold higher risk of
stroke, respectively, in the following year [45,46]. Almost
one in 10 immunocompetent patients with HZ is affected
by at least one non-pain complication [47]. The incidence
of complications becomes more common with increasing
age: patients aged >65 years have four-times the number
of complications than do individuals younger than 35
years [48].
Complications associated with HZ and PHN place a
heavy burden on individuals, who may suffer a perma-
nent reduction in QoL even if the original HZ symptoms
fully resolve [24].
Wider impact of HZ and PHN on QoL
A survey by Weinke et al. was designed to capture the full
course of HZ episodes from rash onset to pain resolution.
The findings demonstrate the major and wide-ranging
impact that HZ, and in particular PHN, have on patients'
QoL [49]. Eleven thousand interviews were conducted in
Figure 1 Association between 'worst pain' score and some interference with individual activities of daily living [36]. Fifty patients with HZ 
were asked to rate their level of pain on a scale from 0 (no pain) to 10 (pain as bad as you can imagine). Interference of pain with seven activities of 
daily living was measured by the Wisconsin Brief Pain Inventory (four of seven daily activities are shown). Some interference was defined as a score of 
≥3. There is a clear correlation between increased pain intensity and greater interference with daily activities and the enjoyment of life. Approximately 
20%-30% of those with moderate pain (score 4) reported that the pain affected their daily activities. At least 51% of those who experienced high levels 
of pain (score 9-10) reported that pain interfered with each activity. Adapted with permission from Lydick et al. [31].
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Germany to evaluate patient-rated pain in historic HZ
episodes and interference with ADL. Screening questions
identified 280 patients ≥50 years old with painful HZ
diagnosed during the previous 5 years, of whom 32
patients developed PHN. Patients with PHN scored sig-
nificantly worse across all outcomes related to pain and
QoL than those with HZ [49]. The mean interference of
pain on different aspects of QoL was highest for sleep,
mood and work [49]. Three-quarters of patients experi-
enced problems in carrying out daily activities, including
work, studies, housework, family and leisure activities
[49]. Approximately 60% of employed interviewees had to
stop work at some point during the active disease period
[49].
When patients' partners were asked how HZ or PHN
had affected patients' QoL, most replied that the symp-
toms interfered considerably with patients' ADL. This
was particularly evident for people who developed PHN
[50]. Not only patients are affected by this disease: caring
for patients with chronic diseases places a burden on
their partners' personal lives and finances [51]. Patients'
partners and family members may need to fill additional
roles. Caring for a person with HZ or PHN may cause
family members to take time off work [52]. Patients and
their partners are less likely to attend or participate in
social occasions [24,51].
HZ-related hospitalizations may contribute to the bur-
den of HZ and PHN on patients and their families [53]. It
is estimated that, in Europe, approximately 12,000 hospi-
talizations each year are due to HZ and its complications
[38,48,54-56]. HZ complications which are likely to lead
to hospitalization are PHN, encephalitis or meningitis
and ocular complications [57]. Of 88,650 estimated
annual cases of HZ in individuals ≥60 years old in Eng-
land and Wales, an estimated 1750 (2%) hospitalizations
are due primarily to HZ [53]. In Connecticut, USA, the
mean annual hospitalization rate due to principal or sec-
ondary diagnosis of HZ over a 10-year period is 16.1/
Figure 2 Impact of post-herpetic neuralgia (PHN) across different 
aspects of quality-of-life (QoL) [13]. A study assessed the impact of 
pain, medication use and QoL in 385 patients with PHN aged >65 
years. Pain causes disruption across many aspects of life for PHN pa-
tients. As many as 40% of respondents said that pain moderately or se-
verely affected their ability to carry out general activities. Forty-eight 
percent of patients commented that pain interfered moderately or se-
verely with their enjoyment of life. Adapted with permission from Os-
ter et al. [13].
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Table 2: The four main domains of complications 
(excluding post-herpetic neuralgia) identified in patients 
with acute herpes zoster (HZ)
Domain Complications
Neurological [20] Vertigo
Cranial nerve palsies (for example, 
facial paresis)
Hearing loss
Varicella zoster virus encephalitis
Motor neuropathy
Myelitis
Small-vessel encephalitis
Granulomatous arteritis with 
secondary stroke
Ophthalmic [74] Ptosis
Scleritis
Iridocyclitis
Secondary glaucoma
Cataract
Keratitis
Blindness
Chorioretinitis
Dermatological [20] Disseminated HZ
Post-herpetic (persisting) pruritus
Secondary bacterial skin infections 
(with subsequent scarring, cellulitis, 
septicaemia)
Visceral [20] Pneumonia
Peri-myocarditis
Hepatitis
Oesophagitis
Myositis
ArthritisJ
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Table 3: Quality-of-life (QoL) scores obtained from patients with herpes zoster (HZ)  compared with different chronic diseases 
SF-36 domain Within two weeks
of HZ onset (n = 46)
Hyper-tension
(n = 2089)
Congestive heart 
failure (n = 216)
Diabetes 
mellitus (n = 541)
Myocardial infarction
(n = 107)
Depression (n = 502)
General health 71 63 47 56 59 53
Vitality 45 58 44 56 58 40
Body pain 35 72 63 69 73 59
Mental health 67 78 75 77 76 46
Role limitations due to emotional 
problems
48 77 64 76 73 39
Physical functioning 63 73 48 68 69 72
Role limitations due to physical 
problems
19 62 34 57 51 44
Social functioning 52 87 71 82 85 57
Modified from [31] and [59].
All scores were calculated using Short Form (SF)-36, a well-validated tool for measuring QoL that has a maximum score of 100; scores under 50 (in bold) represent low QoLJohnson et al. BMC Medicine 2010, 8:37
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100,000 (range, 14.5-18.2) [58]. Almost 67% of these
patients were aged >64 years.
Comparisons between HZ or PHN and chronic conditions
The impact of acute HZ disease on patients' QoL is con-
siderable [36], equalling that seen with common debilitat-
ing chronic conditions such as congestive heart failure,
diabetes mellitus, myocardial infarction and clinical
depression [59] (Table 3). HZ patients have an extremely
low score for role limitations due to physical problems
(scoring 19 out of 100, Table 3). They cannot accomplish
daily duties or fulfil their roles as well as they would nor-
mally expect because of the acute effects of HZ. In
patients with PHN, pain ranks very high compared with
pain from other chronic conditions such as atypical facial
pain, osteoarthritis and rheumatoid arthritis [30].
QoL analysis has been undertaken using data from a
general-population group (including healthy people and
those with a wide range of chronic conditions such as
arthritis, chronic lung disease, congestive heart failure,
diabetes, myocardial infarction or angina and hyperten-
sion; Leplège, unpublished data). Compared with the
mean QoL level for each domain in the general popula-
tion, patients suffering from HZ have poorer QoL scores
(Figure 3) [38]. During the acute phase of HZ, the impact
is clinically meaningful for some domains. For patients
suffering from complications or PHN, the impact is
higher and all the domains are affected (Figure 3) [38].
Current challenges in the treatment of HZ and PHN
Treatment of patients with HZ aims to accelerate rash
healing, relieve pain and reduce complications [5]. Cur-
rent treatments are effective in some patients, but thera-
pies may show limited efficacy and poor tolerability in
others (particularly in the elderly; Table 4).
Despite the development of treatment guidelines by the
International Herpes Management Forum [60], HZ man-
agement is complex [61]. The guidelines recommend oral
antiviral agents for 7 days in patients with HZ who are at
risk of developing PHN (patients aged >50 years with
Figure 3 Quality-of-life (QoL) scores in a French general population cohort versus patients with herpes zoster (HZ) or post-herpetic neural-
gia (PHN) (Leplège, unpublished data; adapted from Figure 2 in Chidiac 2001 [38]). The French general population cohort comprised healthy 
individuals and individuals with various chronic diseases (n = 3656). Average Short-Form-36 (SF-36) scores (eight domains) were calculated for the 
general French population and for patients with acute HZ, HZ-related complications, and PHN. The differences in scores between each patient group 
and the general French population are presented. Patients with HZ and PHN have poorer QoL scores than the general-population group. Clinically 
meaningful differences (scores below -0.5) are observed for some domains in patients with HZ, and for all domains in patients with complicated HZ 
or PHN. All three groups of patients scored low for the SF-36 domains of vitality and mental health.
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severe acute pain, severe rash, or significant prodromal
symptoms) [60]. Studies have shown that aciclovir, valaci-
clovir and famciclovir decrease viral shedding, relieve
acute phase pain, reduce the formation of new lesions
and accelerate healing [5,62,63]. In general, these treat-
ments are well tolerated, even by older patients [37]. By
reducing viral replication, they may decrease the duration
of acute-phase pain and PHN [4,5].
To be effective, antiviral agents must be administered
within 72 h of acute-symptom onset [60], which may be
difficult because of delays in patients seeking medical
advice and delays in reaching diagnosis (for example, due
to presentation of unusual symptoms) [8]. Often, viral
activity and neuronal damage have been ongoing for sev-
eral days before appropriate treatment is given [4]. Even
with prompt treatment, antiviral treatment does not pre-
vent all cases of PHN [37,64]. A recent Cochrane Review
demonstrated that oral acyclovir does not significantly
reduce PHN incidence [64]. The Cochrane review high-
lighted that there is insufficient evidence from random-
ized controlled trials to determine if other antiviral agents
prevent PHN and if these treatments have a beneficial
Table 4: Effect on pain and quality-of-life of agents used to treat herpes zoster (HZ) and/or post-herpetic neuralgia (PHN)
Treatment Advantages Disadvantages
Antiviral agents Relieve acute HZ pain and accelerate lesion healing 
if administered within 72 h of acute-symptom 
onset [8].
Few adverse effects [75,76].
May slightly reduce PHN symptoms and their 
duration [5,8,60,67,71,77-79].
Administration within 72 h is usually not achievable 
[8].
In clinical trials, 20%-30% of treated patients still 
develop PHN [37,71].
Corticosteroids Reduce intensity of pain and overall duration of the 
acute phase [37,80,81].
Significantly accelerate time to uninterrupted 
sleep, return to daily activity, and cessation of 
analgesic therapy.
Do not prevent PHN and produce significant 
adverse events in older adults; their routine use is 
therefore not recommended in elderly patients 
with HZ [37].
Simple analgesics May reduce pain in HZ and PHN [11,75]. Few trials assessing efficacy in HZ or PHN.
Tricyclic antidepressants Provide effective pain relief in PHN patients 
(numbers needed to treat = 2.8) and may possibly 
provide benefits through sedative actions given 
that PHN can induce sleep disturbances and 
anxiety [67].
Side-effects may cause further QoL problems.
Patients do not regain the level of life-satisfaction 
that they had before PHN developed [43,67].
Antiepileptics Gabapentin and pregabalin offer reasonable relief 
for PHN [82-84].
Levels of pain relief are not associated with similar 
improvements in QoL scores [82-84].
Opioids Maximum tolerable doses may reduce PHN pain 
[67].
Side-effects are common and troublesome, 
particularly for elderly patients; overall benefits are 
therefore limited [67].
Topical agents Lidocaine patch provides some pain relief and has 
few side-effects [85].
Capsaicin dermal patch significantly reduces pain 
[86].
Discomfort experienced with capsaicin 
formulations; overall benefits are therefore limited 
[11].
Pain relief with capsaicin dermal patch is not 
associated with improved QoL in PHN [86].
Epidural therapies and 
nerve blocks
Continuous epidural local anaesthetic has been 
shown to effectively treat acute-phase HZ pain [87].
Prolonged (not single-dose or short-term) epidural 
local anaesthetic blockade with corticosteroid may 
provide some protection against PHN [88].
Single-dose epidural local anaesthetic/steroid does 
not prevent PHN [89].
Epidural corticosteroid has potential risk, and 
anecdotal evidence has not supported the benefit.
Prolonged epidural local anaesthetic blockade is 
not practical for widespread use and carries some 
risk [88].Johnson et al. BMC Medicine 2010, 8:37
http://www.biomedcentral.com/1741-7015/8/37
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impact on QoL [64]. Twenty studies of antiviral treatment
for acute HZ were identified, but 14 were excluded from
the Cochrane review, mainly because of limitations with
the study design.
A recent Canadian study of patients with HZ rash or
pain showed that pain resolution is associated with
recovery of QoL to a pre-morbid state (personal commu-
nication). Data showed that the median duration of pain
was equal to the median duration of QoL impairment.
Once established, the pain associated with HZ or PHN is
difficult to treat [65]. PHN remains largely refractory to
pharmacological treatments and prevention strategies
[66]. Data show that >50% of patients require more than
one prescription drug for PHN [13]. Despite treatment,
s ym p t o m a t i c  r e l i e f  is  o b t a i n ed  i n  o n l y  5 0 %  o f  pa t i e n ts
[67]. Patients with PHN experience significantly less pain
relief than those with HZ, despite receiving more pain
medications (mean, 2.2 versus 1.6) [49]. Studies have
assessed the 'number needed to treat' for existing PHN
therapies (how many patients need to be treated n order
to achieve at least 50% pain relief in one patient compared
with the controls). Data highlight the limited pain relief
obtained in PHN patients. For some standard treatments,
approximately four patients with PHN need to be treated
in order to achieve pain relief in one patient (Figure 4)
[68].
As patients with PHN may find it difficult to tolerate
pain therapies, drug doses are often titrated. This may
result in several weeks of suboptimal treatment, during
which it is unclear if (or when) the drugs will become
effective [67]. Therapeutic compliance is also difficult to
achieve. Almost 50% of patients with PHN do not discuss
their symptoms regularly with physicians [13]. One in 10
is troubled substantially by the side-effects of PHN treat-
ments [13,24].
Treatment dissatisfaction is high in patients with PHN.
In one study, only 14% of patients aged >65 years were
satisfied with pain medication for PHN [13]. In the survey
by Weinke et al. [49], patient-reported satisfaction with
HZ treatments was significantly lower in patients with
PHN versus those with HZ (6.8 versus 8.3; scale from 0,
'not satisfied' to 10, 'very satisfied').
Vaccination may reduce the burden of HZ disease
Current treatment strategies for HZ and PHN are only
partially effective, so reducing the burden of HZ disease
remains an area of considerable need [11]. A solution is
for proactive strategies to focus on HZ prevention [67].
At least one study has shown that, compared with people
who have not experienced HZ, those who have had HZ or
PHN place higher value on preventing this disease. In this
study, both groups questioned (community members and
patients with HZ or PHN) said that they would be willing
to pay substantial amounts of money to prevent HZ [69].
The clinical rationale for the development of an HZ
vaccine has centred on reducing the severity of HZ and
PHN. Studies have shown that the live attenuated Oka/
Merck VZV vaccine ('zoster vaccine') also reduced the
incidence of HZ and PHN in addition to burden of illness
(a severity-by-duration measure of the total pain and dis-
comfort associated with a disease). Evidence that the
zoster vaccine reduces HZ burden in an ageing popula-
tion is derived from the Shingles Prevention Study [70].
The Shingles Prevention Study had a randomized, dou-
ble-blind, placebo-controlled design and assessed HZ
burden of illness and PHN incidence (pain rated as ≥3 on
a 0-10 scale ≥90 days after rash onset) in >38,000 people
aged ≥60 years who received zoster vaccine or placebo.
Compared with placebo, vaccination significantly
reduced HZ burden of illness by 61.1%. Vaccine recipi-
ents had a significantly reduced incidence of HZ (-51%)
and PHN (-67%) compared with placebo [70,71]. HZ
symptoms in the vaccine group were, in general, milder
and of shorter duration than those in the placebo group
[70,71]. Vaccination reduced PHN incidence defined
using alternative cut-off times for the duration (persis-
tence) of pain; the reduction in incidence was 72.9% at
180 days (Figure 5) [70,71]. Although the reduction in HZ
incidence with vaccine compared with placebo was less
apparent in patients who were aged ≥70 years versus
those aged 60-69 years, the reductions in HZ burden of
illness and PHN were preserved in the older population
[70].
In an adverse event substudy of the Shingles Prevention
Study, rates of serious adverse events were higher in the
vaccine group (1.9%) than in the placebo group (1.3%)
[70]. Injection site reactions were more frequent among
Figure 4 Number needed to treat with common pain therapies to 
obtain 50% pain relief in one patient [68]. Data highlight the limited 
relief from pain obtained in patients with post-herpetic neuralgia 
(PHN). For some treatments, approximately four patients with PHN 
need to be treated to achieve 50% pain relief in one patient.
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vaccine recipients than those taking placebo (48.3% ver-
sus 16.6%, respectively), but were generally mild.
The impact of vaccination on QoL was assessed in the
entire study population of the Shingles Prevention Study
using ZBPI and ZIQ questionnaires. Mean ZBPI and ZIQ
scores, which rated the 'interference' of HZ and PHN with
ADL, were used to calculate a 'severity of interference
score'. For the entire study population, zoster vaccination
reduced the ZBPI severity of interference by 66% (95%
confidence interval; CI: 55, 74) and the ZIQ severity of
interference by 68% (95% CI: 57, 77). In individuals who
developed HZ, vaccination reduced the ZBPI severity of
interference by 31% (95% CI: 12, 51) and the ZIQ severity
of interference by 35% (95% CI: 13, 57). Zoster vaccina-
tion therefore reduced the burden of HZ-related interfer-
ence with ADL by about two-thirds in a population of
older adults and by about one-third in vaccine recipients
who developed disease [72]. Much of the effectiveness of
the zoster vaccination was due to the prevention of HZ
episodes [70-73].
Summary
HZ is a common disease that can substantially reduce
patients' QoL and functional status. HZ is rare in young
individuals, but there is a marked increase in risk after 50
years of age. The consequences of HZ are a particular
problem in older individuals. In part, this may be due to
slow healing of nerve damage and inflammatory scarring
in an ageing nervous system. The number of cases of HZ
and PHN is expected to increase in coming decades due
to the steady rise in the mean age of the population.
Pain is the major symptom that affects the QoL and
ADL of patients and is usually present across all phases of
HZ disease. In patients whose pain persists for months or
Figure 5 Duration of pain in vaccine recipients in the Shingles Prevention Study [70]. The graph compares vaccine recipients who developed 
herpes zoster and post-herpetic neuralgia (PHN; 315/19,254 recipients) with placebo recipients who developed disease (641/19,247 recipients). Com-
pared with placebo, Zostavax reduced PHN incidence defined as pain at different cut-off times for the duration of pain. Pain persisting at 90 days was 
reduced by 67%. * For the total population and the sub-groups stratified according to sex, the incidence of PHN in each treatment group (vaccine or 
placebo) was the weighted average of the observed incidence of PHN stratified according to age group, with weights proportional to the total num-
ber of person-years of follow-up in each age group.
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years as PHN, the effects on patients' lives can be devas-
tating. The negative effects of HZ and PHN on physical,
social, functional and psychological health are as sub-
stantial as the effects described by patients with other
chronic health conditions. Non-pain-related complica-
tions of HZ may also contribute to a reduced QoL. HZ
and PHN can also have significant consequences for
patients' partners, relatives and social circle.
To be effective, antiviral medication needs to be started
within 72 h of the onset of acute symptoms. Antiviral
agents show limited efficacy if administered within 72 h
of acute-symptom onset. Treatment within this time is
often not achievable and patients may present with pain
that is established and difficult to treat. Current treat-
ments for PHN are largely suboptimal and often accom-
panied by intolerable side-effects. Awareness of these
challenges and the substantial burden of HZ and PHN on
patients' QoL may lead to improved prevention and man-
agement strategies.
Zoster vaccine has been demonstrated to attenuate the
severity of HZ disease and significantly reduce the inci-
dence of HZ and PHN. The introduction of a prophylac-
tic vaccination scheme may achieve a significant positive
impact on the incidence and course of HZ disease,
thereby improving patients' QoL.
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